Key result
NHE-1 inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models, suggesting they could emerge as important therapeutic tools for the treatment of heart failure.
Why the study?
Do Na-H exchange (NHE-1) inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models?
Population
In vitro and in vivo models of heart failure and cardiac hypertrophy
Design
Review
Authors
Loading...
NHE-1 inhibitors should not yet alter heart failure care; leaves open their potential pending clinical translation.
Do Na-H exchange (NHE-1) inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models?
Preclinical evidence indicates that NHE-1 inhibitors have therapeutic potential to attenuate maladaptive cardiac remodeling and heart failure, particularly after myocardial infarction.
Morris Karmazyn (2001) conducted a review in Heart failure. Na-H exchange (NHE-1) inhibitors was evaluated. NHE-1 inhibitors attenuate cardiomyocyte hypertrophy and heart failure in preclinical models, suggesting they could emerge as important therapeutic tools for the treatment of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: